tsn

Merck Positioning to Take the Lead U.S. COVID-19 Antiviral Market from Remdesivir: EIDD-2801

 18245
0 comment
Staff at TrialSite | Quality Journalism
Jul. 25, 2020, 5:30 p.m.

In May, Merck announced a collaboration with Ridgeback Biopharmaceuticals LP (Ridgeback) to jointly develop EIDD-2801, an orally available antiviral candidate currently in early development for the treatment of patients with COVID-19. Influential sources have conveyed to the TrialSite that the intention will be to demonstrate superiority over Gilead’s Remdesivir as some scientists believe the product will evidence greater efficacy with the added benefit of oral availability. Remdesivir presently requires intravenous administration, and the rumblings are that forthcoming results from large global studies could disappoint. The early movers don’t always win in emerging markets, and the COVID-19 antiviral market is definitely an unfolding one. In the meantime, Gilead launched a study to test an inhalable version of the drug.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month 
which is less than a Starbucks coffee!

Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2025 - Trial Site News